



国内版 国际版

The significance of postoperative follow-up of patients with m



Chat with Bing

Sign in



All

Images

Videos

开启取词

Add Bing Firefox extension >

35,100 Results

Any time ▾

Prognostic value of circulating tumor DNA in patients with ...

journals.plos.org/plosone/article?id=10.1371/journal.pone.0171991 ▾

The application of circulating tumor DNA(ctDNA) represents a non-invasive method for tumor detection. Its prognostic significance in patients with colorectal cancer is controversial. We performed a systematic review of data from published studies to assess the prognostic values of ctDNA in patients with colorectal cancer.

Cited by: 21

Author: Gaowei Fan, Kuo Zhang, Xin Yang, Jians...

Publish Year: 2017

Prognostic Value of Postoperative Detection of Blood ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1514320>

Postoperative detection of blood circulating tumor cells had no prognostic significance in patients with colorectal cancer operated on for cure. Despite advances in surgical and adjuvant treatments, up to 30% to 40% of patients with resectable colorectal cancer (CRC) develop tumor relapse during follow-up.

Cited by: 79

Author: Xavier Bessa, Virginia Piñol, Sergi Castell...

Publish Year: 2003

Circulating tumor DNA as an early marker of therapeutic ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511218>

Apr 07, 2015 : In this work, we describe the potential role of ctDNA as an early predictor of treatment response of patients with metastatic colorectal cancer (mCRC) undergoing chemotherapy and as a marker of disease bulk that could complement RECIST.

Cited by: 263

Author: Jeanne Tie, I. Kinde, Y. Wang, H. L. Won...

Publish Year: 2015

Prognostic significance of circulating tumor cells in ...

<https://academic.oup.com/annonc/article/20/7/1223/345403> ▾

Mar 12, 2009 - Background: We demonstrated that circulating tumor cell (CTC) number at baseline and follow-up is an independent prognostic factor in metastatic colorectal cancer (mCRC). This analysis was undertaken to explore whether patient and treatment characteristics impact the ...

Cited by: 474

Author: S.J. Cohen, C.J.A. Punt, N. Iannotti, B.H....

Publish Year: 2009

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 52253

Manuscript Type: ORIGINAL ARTICLE

Prospective Study

Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA

Benešová L *et al.* CtDNA in detection of mCRC recurrence

Lucie Benešová, Tereza Hálková, Renata Ptáčková, Anastasiya Semyakina, Kateřina Menclová, Jiří Pudil, Miroslav Ryska, Miroslav Levý, Jaromír Šimša, Filip Pazdírek, Jiří Hoch, Milan Blaha, Marek Minárik

Abstract

BACKGROUND

One of the most notable applications for circulating tumor DNA (ctDNA) detection in peripheral blood of patients with metastatic colorectal cancer (mCRC) is a long-term

Match Overview

1	Internet 67 words crawled on 29-Nov-2016 www.ce-ce.org	2%
2	Internet 13 words livrepository.liverpool.ac.uk	<1%
3	Internet 13 words crawled on 17-Jun-2019 perihalbarah.blogspot.com	<1%
4	Internet 12 words crawled on 28-Jul-2016 cellandbioscience.biomedcentral.com	<1%



国内版 国际版

Significance of postoperative follow-up of patients with meta



All

Images

Videos

关闭取词

46,200 Results

Any time ▾

Circulating tumor DNA as an early marker of therapeutic ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511218>

Apr 07, 2015 · Early indicators of treatment response in **metastatic colorectal cancer** (mCRC) could conceivably be used to optimize treatment. We explored early changes in **circulating tumor DNA** (ctDNA) levels as a marker of therapeutic efficacy. This prospective study involved 53 mCRC **patients** ...

Cited by: 272

Author: Jeanne Tie, I. Kinde, Y. Wang, H. L. Wong, J....

Publish Year: 2015

Prognostic Potential of Circulating Tumor DNA Measurement ...

<https://jamanetwork.com/journals/jamaoncology/fullarticle/2733131> ▾

Findings In this study of 58 **patients** with resected, nonmetastatic **colorectal cancer**, 45 **patients** with negative **circulating tumor DNA** levels were recurrence-free, whereas 10 of 13 **patients** with positive **circulating tumor DNA** levels relapsed during **follow-up**. **Circulating tumor DNA** positivity preceded radiologic or clinical evidence of recurrence ...

Clinical utility of circulating tumor DNA for colorectal ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447957>

Mar 04, 2019 · Time-course analysis of **tumor**-specific mutations in the blood of **patients** is useful to monitor a response and resistance to molecular targeted drugs. For example, we describe a **patient with metastatic colorectal cancer** treated with EGFR inhibitor. **Circulating tumor DNA** allows us to identify, track, and quantify clones bearing distinct alleles.

Cited by: 1

Author: Hiroki Osumi, Eiji Shinozaki, Kensei Yamag...

Publish Year: 2019

Prognostic significance of circulating tumor cells in ...

<https://academic.oup.com/annonc/article/20/7/1223/345403> ▾

Mar 12, 2009 · Background: We demonstrated that **circulating tumor cell** (CTC) number at baseline and **follow-up** is an independent prognostic factor in **metastatic colorectal cancer** (mCRC). This analysis was undertaken to explore whether **patient** and treatment characteristics impact the ...

Cited by: 490

Author: S.J. Cohen, C.J.A. Punt, N. Iannotti, B.H. Sa...

Publish Year: 2009

Prognostic Potential of Circulating Tumor DNA Measurement ...

https://www.researchgate.net/publication/333000026_Prognostic_Potential_of_Circulating...

The aim of this study is to review the evidence of the impact of different **follow-up** strategies in **patients** with non-**metastatic colorectal cancer** after curative surgery, in relation to overall ...



ALL

IMAGES

VIDEOS

关闭取词

31,200 Results

Any time ▼

Circulating tumor DNA as an early marker of therapeutic ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511218>

Apr 07, 2015 · Digital approaches to DNA analysis can now enable rapid identification of **somatic tumor mutations** and subsequent quantification of **circulating tumor DNA (ctDNA)** [7–9]. While previous studies have demonstrated that ctDNA is detectable in a high proportion of **patients with metastatic disease** [10 – 12], the clinical utility of ctDNA as a **cancer biomarker** is just beginning to be evaluated.

Cited by: 272

Author: Jeanne Tie, I. Kinde, Y. Wang, H. L. Won...

Publish Year: 2015

Prognostic Potential of Circulating Tumor DNA Measurement ...

<https://jamanetwork.com/journals/jamaoncology/fullarticle/2733131> ▼

Aug 01, 2019 · Meaning Serial **circulating tumor DNA** levels during **postoperative surveillance** can be used as a **triage test to stratify patients with resected colorectal cancer** on the basis of their risk of recurrence.

Cited by: 5

Author: Yuxuan Wang, Lu Li, Joshua D. Cohen, I...

Publish Year: 2019

Prognostic significance of circulating tumor cells in ...

<https://academic.oup.com/annonc/article/20/7/1223/345403> ▼

Mar 12, 2009 · Background: We demonstrated that circulating tumor cell (CTC) number at baseline and **follow-up** is an independent **prognostic factor in metastatic colorectal cancer (mCRC)**. This analysis was undertaken to explore whether **patient and treatment characteristics impact the ...**

Cited by: 490

Author: S.J. Cohen, C.J.A. Punt, N. Iannotti, B.H....

Publish Year: 2009

Circulating tumour DNA (ctDNA) as a biomarker in ...

<https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-6336-3> ▼

Nov 14, 2019 · Circulating **tumour DNA (ctDNA)** has emerged as a promising blood-based biomarker for **monitoring disease status of patients with advanced cancers**. The presence of ctDNA in the blood is a result of biological processes, namely **tumour cell apoptosis and/or necrosis**, and can be used to monitor different **cancers by targeting cancer-specific mutation**.

Author: Leslie Calapre, Lydia Warburton, Mich... Publish Year: 2019